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Objective
To assess the ability of patients, during an acute migraine
attack, to successfully self-inject a single dose of suma-
triptan using the Alsuma Auto-Injector; and to evaluate
the safety and tolerability of the Auto-Injector.
Background
The Alsuma Auto-Injector is a single-use system for the
rapid subcutaneous delivery of 6 mg of sumatriptan suc-
cinate in the acute management of migraine pain. The
Auto-Injector was developed to address the clinical need
for an easy to use and rapid to administer system that did
not require any assembly.
Methods
This was an open-label, Phase 3 trial conducted at 10 sites
in the US. Male or female adults, ages 18 to 60 years old,
were eligible for study entry if they met IHS criteria for
migraine with or without aura, with at least 2 attacks per
month, and if they reported use of subcutaneous injectable
sumatriptan on at least 2 occasions within the previous
2 months. During the onset of a migraine attack of moder-
ate-to-severe intensity, patients were asked to administer
a 6 mg subcutaneous dose of sumatriptan using the
Auto-Injector. Subjects returned to the study site within
72 hours of the migraine for the post-treatment assess-
ment visit.
Results
A total of 63 patients met entry criteria and received a
dose of study medication. All self-administered the
Alsuma Auto-Injector successfully. On the patient ques-
tionnaire, 100% of patients agreed that the written
instructions for the Auto-Injector were clear and easy to
follow, and that the Auto-Injector was easy to use (95%).
A majority of patients agreed that they preferred the new
Auto-Injector to the traditional one that they were using
prior to study entry (65.1%). The most frequent AEs was
injection site bruising, reported by 15.9% of patients, and
rated in all instance as mild in intensity.
Conclusion
The majority of injection-experienced patients reported
the pre-assembled, single-use Alsuma Auto-Injector to be
an easy to use, preferred treatment for an acute migraine
attack. The study found the Auto-Injector to be safe and
well-tolerated.
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